Longevica – a US-based innovation company – has dedicated more than a decade to researching compounds that could improve the human lifespan, and its long-term research on longevity could soon result in lifespan-extending supplement production.
The company has managed to raise a whopping $13 million from various investors, one of which is Alexander Chikunov, the biotech company’s chairman. Consequently, the revolutionary supplements could find their way to the shelves very soon—probably even by the end of this year.
After examining the lifespan of laboratory mice, Longevica created a biotechnology platform for longevity research. They currently aim at producing medications, foods, and dietary supplements.
Longevity is a growing sector for technology start-ups, and many companies are joining the ranks. This research also attracts many investors. Only in 2018, start-ups tackling life expansion raised a record $800 million.
The CEO of Longevica, Ainar Abdrakhmanov, emphasized the increased need to prolong the human life span. He also reminded that according to WHO, two billion people will be above the age of 60 by 2050. Furthermore, experts predict that the sales of supplements and services for senior consumers will reach about $27 by 2026. For the sake of comparison, the sales merely hit $17 trillion in 2019.
Longevica’s team of researchers led by Alexey Ryazanov examined more than 20,000 female mice with a long lifespan and 1,033 pharmaceuticals in 62 pharmacological classes to identify substances that increase longevity.
The large-scale screening identified five chemicals that could potentially prolong life. These are Pentetic Acid, D-Valine, Clofibrate, Inulin, and Proscillaridin A. Additionally, the researchers also obtained data on metals’ and toxins’ removal from the body.
All in all, the dream of prolonging the human lifespan might be closer to fulfillment than we imagined. If everything goes according to plan, we might enjoy these miraculous supplements in less than a year. All we have to do now is wait.